Last Name	First Name	Middle Name	Signature/Date:
Osmundsen	Erica		
Credentials: BA, CCRC			**Title:** Study Coordinator
Study Site Address(es): WR-ClinSearch, LLC 6035 Shallowford Rd, Suite 109 Chattanooga, TN, 37421			**Contact Information** **Phone:** 423-698-4584 **Fax:** 423-698-4577 **Email:** eosmundsen@clinsearch-us.com

Education and Training:
Vanderbilt University, Nashville, TN, BA-Psychology, Honors Program, Minor: English, Magna Cum Laude, 2000

Positions and Employment:

Date(s)	Title	Institution/Company
2011-Present	Clinical Research Coordinator, Regulatory, Data, and Start-Up Specialist	WR-ClinSearch, LLC, Chattanooga, TN
2008-2011	Program Developer	Cross Country Education, Brentwood, TN
2002-2008	Operations Development Manager/Patient Recruitment Coordinator	Praxis Communications, Brentwood, TN
2001-2002	Case Manager-Adult Mental Illness	Centerstone Health, Nashville, TN
2000-2002	Clinical Research Coordinator	Vanderbilt Psychiatric Hospital Psychopharmacology Department, Nashville, TN
1996-2000	Clinical Research Assistant	Vanderbilt Psychiatric Hospital Psychopharmacology Department, Nashville, TN

Professional Certification/Licensure:
CCRC (ACRP Certified), 2013
CPR Certification, 2013
OSHA-Blood Borne Pathogens Training, 2013
IATA-Shipping Dangerous Goods Training, 2014

Clinical Study Phase Experience: I, II, III

Clinical Research Experience:

- A 12-Week, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Safety and Efficacy of XXXX in Patients with Diabetic Gastroparesis
- A 52-Week, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Safety and Efficacy of XXXX in Patients with Diabetic Gastroparesis
- A 46-Week, Double-Blind, Placebo-controlled, Phase III Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of XXXX in patients with Diabetic Gastroparesis
- A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of XXXX for Treatment of Fibromyalgia
- A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of XXXX Administered Once Daily for 6 Weeks in Adults with Nonalcoholic Fatty Liver Disease
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of XXXX Lotion in the Treatment of Acne Vulgaris for 12 Weeks

- A Randomized, Phase II, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of XXXX, YYYY and ZZZZ in Adult Subjects with Active Sjogren's Syndrome
- A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of XXXX for the Treatment of Pruritus in Adults and Adolescents with a History of Atopic Dermatitis
- A Parallel Group, Double-Blind, Randomized, Placebo controlled Phase III Trial to Evaluate the Efficacy and Safety of XXXX Administered Intravenously in Patients with Chronic Migraine
- An Open Label Phase III Trial to Evaluate the Safety of XXXX Administered Intravenously in Patients with Chronic Migraines
- A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding study of XXXX in the treatment of acute Migraine
- Double-Blind, Randomized, Placebo controlled, Dose-ranging Trial of XXXX for Acute Migraine Treatment
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XXXX in Patients with Migraine
- A Phase III, Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-Dose Combination XXXX in Subjects with Moderately to Severely Active Crohn's Disease
- A Phase IIa Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study of Oral XXXX Administered Once and Twice Daily to Patients with Diabetic Gastroparesis
- A Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXXX Administered Intravenously in Patients with Chronic Migraine
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effects of XXXX on Gastric Emptying Time in Diabetic Subjects with Gastroparesis
- A Phase III, Multicenter, Open-Label, Safety and Tolerability Extension Trial of XXXX Daily in the Treatment of Chronic Idiopathic Constipation
- Comparison of the Performance of the XXXX Test and FIT Post Colonoscopy in Subjects with Colorectal Cancer and Pre Colonoscopy in Subjects from a Guideline-Eligible Screening Population
- A Phase II, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Female Subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- A Phase III, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, Followed by a Four Week Randomized Withdrawal to Evaluate the Efficacy and Safety of Oral XXXX Once Daily in Female Patients with IBS-D
- A Phase III, Multicenter Study to Assess Repeat Treatment Efficacy and Safety of XXXX TID in Subjects with IBS-D
- A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Assess the Safety and Efficacy of XXXX for the Treatment of Opioid Inducted Constipation (OIC) in Patients with Non-Malignant Chronic Pain Receiving Opioid Therapy
- A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX in Patients with Chronic Idiopathic Constipation (CIC)
- A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of XXXX versus Polyethylene Glycol 3350 (PEG 3350) for Opioid-Induced Constipation (OIC)
- A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Dose-finding Study to Evaluate Efficacy of a Novel Selective 5-HT4 Receptor Agonist, XXXX Taken with a PPI in Subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation with or without Heartburn while on PPI Therapy
- A Phase IIIb, Multicenter, Randomized, Active-Control, Study to Evaluate the Cardiovascular Safety XXXX and ZZZZ in Subjects with Gout and Cardiovascular Comorbidities
- A Randomized, Double-blind, Placebo-controlled, Parallel-group study to Evaluate Long-Term Treatment with XXXX on MACE and Type 2 Diabetes in Obese Subjects with Cardiovascular Risk Factors
- A Randomized, Double Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study XXXX Topical-Gel to YYYY Topical Gel in the Treatment of Acne Vulgaris
- A Double Blind, Randomized, Parallel Group, Vehicle-Controlled, Multicenter Study Comparing XXXX to Reference Listed Drug in the Treatment of Acne Vulgaris
- Comparative Effectiveness of Antipsychotic Medications in patients with Schizophrenia (CATIE) NIMH Study
- A Phase III, Multicenter, Double-Blind Study to Assess the Efficacy and Safety of XXXX Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Rater Certifications:

C-SSRS